Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.21 USD | -0.57% | -9.55% | -42.05% |
Financials (USD)
Sales 2024 * | 227M | Sales 2025 * | 282M | Capitalization | 743M |
---|---|---|---|---|---|
Net income 2024 * | 9M | Net income 2025 * | 71M | EV / Sales 2024 * | 1.53 x |
Net cash position 2024 * | 395M | Net cash position 2025 * | 448M | EV / Sales 2025 * | 1.05 x |
P/E ratio 2024 * |
89.8
x | P/E ratio 2025 * |
11
x | Employees | 300 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.93% |
Latest transcript on Aurinia Pharmaceuticals Inc.
1 day | -0.57% | ||
1 week | -9.55% | ||
Current month | +2.36% | ||
1 month | +3.58% | ||
3 months | -12.44% | ||
6 months | -43.18% | ||
Current year | -42.05% |
Managers | Title | Age | Since |
---|---|---|---|
Michael Martin
FOU | Founder | 52 | 93-06-15 |
Peter Greenleaf
CEO | Chief Executive Officer | 54 | 19-04-28 |
Robert Foster
FOU | Founder | 65 | 93-06-15 |
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Foster
FOU | Founder | 65 | 93-06-15 |
R. MacKay-Dunn
BRD | Director/Board Member | 73 | 19-06-25 |
Peter Greenleaf
CEO | Chief Executive Officer | 54 | 19-04-28 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.10% | 0 M€ | 0.00% | - | |
0.05% | 0 M€ | 0.00% | - | |
0.01% | 9 M€ | -.--% | - | |
0.01% | 746 M€ | -.--% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-24 | 5.21 | -0.57% | 681,996 |
24-05-23 | 5.24 | -5.24% | 1,049,103 |
24-05-22 | 5.53 | -1.07% | 889,815 |
24-05-21 | 5.59 | -3.29% | 1,392,676 |
24-05-20 | 5.78 | +0.35% | 2,414,171 |
Delayed Quote Nasdaq, May 24, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-42.05% | 743M | |
+12.30% | 118B | |
+12.15% | 106B | |
-8.14% | 23.4B | |
-1.69% | 21.78B | |
-10.60% | 18.09B | |
-41.25% | 16.72B | |
-15.33% | 15.97B | |
+5.80% | 14.03B | |
+28.03% | 11.67B |
- Stock Market
- Equities
- AUPH Stock